[(1S,2S)-2-氨基环丙基]氨基甲酸叔丁酯 | 847268-25-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: [(1S,2S)-2-氨基环丙基]氨基甲酸叔丁酯
• 英文名称: (-)-(1S,2S)-N-mono(tert-butoxycarbonylamino)cyclopropanediamine
• 英文别名: tert-butyl (1S,2S)-2-aminocyclopropylcarbamate；tert-butyl N-[(1S,2S)-2-aminocyclopropyl]carbamate
• CAS: 847268-25-1
• 化学式: C₈H₁₆N₂O₂
• mdl: MFCD09863455
• 分子量: 172.227
• InChiKey: XDHLWTHTPXBYLH-WDSKDSINSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.875
• 拓扑面积：
  64.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  [(1S,2S)-2-氨基环丙基]氨基甲酸叔丁酯 在 lithium hydroxide 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 四氢呋喃 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 11.0h， 生成 N-[(2S)-(tert-butoxycarbonylamino)cycloprop-(1S)-yl]-N-(thymin-1-ylacetyl)glycine
  参考文献：
  名称：

  Cyclopropane PNA: observable triplex melting in a PNA constrained with a 3-membered ring

  摘要：

  The first peptide nucleic acid (PNA) with a cyclopropane in the backbone has been synthesized, and the effects of the ring on DNA/RNA binding properties of the PNA have been examined. Well-defined triplex to duplex melting transitions of PNA(2) DNA complexes is clearly observed by variable temperature UV absorbance with the cyclopropane-constrained PNA. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2004.12.061
• 作为产物：
  描述：

  (-)-(1S,2S)-di(tert-butoxycarbonylamino)cyclopropane 在 三氟乙酸 作用下， 以 乙醚 为溶剂， 反应 12.0h， 以45%的产率得到[(1S,2S)-2-氨基环丙基]氨基甲酸叔丁酯
  参考文献：
  名称：

  Cyclopropane PNA: observable triplex melting in a PNA constrained with a 3-membered ring

  摘要：

  The first peptide nucleic acid (PNA) with a cyclopropane in the backbone has been synthesized, and the effects of the ring on DNA/RNA binding properties of the PNA have been examined. Well-defined triplex to duplex melting transitions of PNA(2) DNA complexes is clearly observed by variable temperature UV absorbance with the cyclopropane-constrained PNA. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2004.12.061

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DU RÉCEPTEUR DU FACTEUR DE CROISSANCE DES FIBROBLASTES
  申请人：GUANGDONG NEWOPP BIOPHARMACEUTICALS CO LTD

  公开号：WO2020119606A1

  公开（公告）日：2020-06-18

  Disclosed are heterocyclic compounds as inhibitors of FGFR-4 represented by formula (I). Also disclosed is a pharmaceutical composition that includes an inhibitor of FGFR-4. The compounds maybe used to treat diseases mediated with abnormality of FGFR-4 and /or FGF19, such as hepatocellular carcinoma and other forms of cancer.

  本发明涉及一种以式(I)表示的FGFR-4抑制剂的杂环化合物。还公开了一种包含FGFR-4抑制剂的药物组合物。这些化合物可用于治疗由FGFR-4和/或FGF19异常介导的疾病，如肝细胞癌和其他形式的癌症。
• Metallo-beta-lactamase inhibitors
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10221163B2

  公开（公告）日：2019-03-05

  The present invention relates to metallo-beta-lactamase inhibitor compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein Z, RA, X1, X2 and R1 are as defined herein. The present invention also relates to compositions which comprise a metallo-beta-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta-lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more β-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.

  本发明涉及式 I 的金属-β-内酰胺酶抑制剂化合物：及其药学上可接受的盐，其中 Z、RA、X1、X2 和 R1 如本文所定义。本发明还涉及组合物，其包含本发明的金属-β-内酰胺酶抑制剂化合物或其药学上可接受的盐，以及药学上可接受的载体，可选择与β-内酰胺抗生素和/或β-内酰胺酶抑制剂结合使用。本发明进一步涉及治疗细菌感染的方法，包括向患者施用治疗有效量的本发明化合物，与治疗有效量的一种或多种β-内酰胺类抗生素联合使用，也可选择与一种或多种β-内酰胺酶抑制剂化合物联合使用。本发明的化合物在本文所述的克服抗生素耐药性的方法中是有用的。
• METALLO-BETA-LACTAMASE INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20190144432A1

  公开（公告）日：2019-05-16

  The present invention relates to metallo-β-lactamase inhibitor compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein Z, R A , X 1 , X 2 and R 1 are as defined herein. The present invention also relates to compositions which comprise a metallo-β-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more β-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.
• Cyclopropane PNA: observable triplex melting in a PNA constrained with a 3-membered ring
  作者：Jonathan K. Pokorski、Michael C. Myers、Daniel H. Appella

  DOI：10.1016/j.tetlet.2004.12.061

  日期：2005.2

  The first peptide nucleic acid (PNA) with a cyclopropane in the backbone has been synthesized, and the effects of the ring on DNA/RNA binding properties of the PNA have been examined. Well-defined triplex to duplex melting transitions of PNA(2) DNA complexes is clearly observed by variable temperature UV absorbance with the cyclopropane-constrained PNA. (C) 2004 Elsevier Ltd. All rights reserved.